These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29197742)

  • 21. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
    Schrey D; Speitel K; Lanvers-Kaminsky C; Gerss J; Möricke A; Boos J
    Pediatr Blood Cancer; 2011 Sep; 57(3):378-84. PubMed ID: 21337682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
    Narta UK; Kanwar SS; Azmi W
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):208-21. PubMed ID: 17011787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A journey through the lectin pathway of complement-MBL and beyond.
    Garred P; Genster N; Pilely K; Bayarri-Olmos R; Rosbjerg A; Ma YJ; Skjoedt MO
    Immunol Rev; 2016 Nov; 274(1):74-97. PubMed ID: 27782323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
    Avramis VI; Panosyan EH
    Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia.
    Mayilyan KR; Arnold JN; Presanis JS; Soghoyan AF; Sim RB
    Neurosci Lett; 2006 Sep; 404(3):336-41. PubMed ID: 16860475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation.
    Kocsis A; Kékesi KA; Szász R; Végh BM; Balczer J; Dobó J; Závodszky P; Gál P; Pál G
    J Immunol; 2010 Oct; 185(7):4169-78. PubMed ID: 20817870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum MASP-1 in complex with MBL activates endothelial cells.
    Megyeri M; Jani PK; Kajdácsi E; Dobó J; Schwaner E; Major B; Rigó J; Závodszky P; Thiel S; Cervenak L; Gál P
    Mol Immunol; 2014 May; 59(1):39-45. PubMed ID: 24472859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
    Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
    Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assays for the functional activity of the mannan-binding lectin pathway of complement activation.
    Thiel S; Møller-Kristensen M; Jensen L; Jensenius JC
    Immunobiology; 2002 Sep; 205(4-5):446-54. PubMed ID: 12396006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
    Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
    Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
    Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
    J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi.
    Cestari Idos S; Krarup A; Sim RB; Inal JM; Ramirez MI
    Mol Immunol; 2009 Dec; 47(2-3):426-37. PubMed ID: 19783051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegaspargase for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.